Enanta Pharma (ENTA) Tops Q4 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2015
November 23, 2015 4:01 PM ESTConference Call and Webcast Today at 4:30 p.m. ET
Royalty revenue of $14.4 million in fourth quarter brings fiscal year total to $34.1 million AbbVies phase 3 trial begun for next-generation HCV treatment containing Enantas protease inhibitor ABT-493 Enantas cyclophilin inhibitor candidate EDP-494 expected to enter the clinic in the first calendar quarter of 2016 Cash and marketable securities totaled $209 million at September 30, 2015WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc., (NASDAQ:... More
